Abstract
PPARγ is a nuclear receptor that has a dominant regulatory role in differentiation of cells of the adipose lineage, and has recently been shown to be expressed in the colon. We show here that PPARγ is expressed at high levels in both well- and poorly-differentiated adenocarcinomas, in normal colonic mucosa and in human colon cancer cell lines. Ligand activation of this receptor in colon cancer cells causes a considerable reduction in linear and clonogenic growth, increased expression of carcinoembryonic antigen and the reversal of many gene expression events specifically associated with colon cancer. Transplantable tumors derived from human colon cancer cells show a significant reduction of growth when mice are treated with troglitazone, a PPARγ ligand. These results indicate that the growth and differentiation of colon cancer cells can be modulated through PPARγ.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mangelsdorf, D.J. et al. The nuclear receptor superfamily: the second decade. Cell 83, 835–839 ( 1995).
Spiegelman, B.M. & Flier, J.S. Adipogenesis and obesity: rounding out the big picture. Cell 87, 377–389 (1996).
Lehmann, J.M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma. J. Biol. Chem. 270, 12953–12956 ( 1995).
Lehmann, J.M., Lenhard, J.M., Oliver, B.B., Ringold, G.M. & Kliewer, S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272, 3406–3410 (1997).
Kliewer, S.A. et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83, 813–819 (1995).
Forman, B.M. et al. 15-deoxy-Delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83, 803–812 (1995).
Kliewer, S.A. et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptor alpha and gamma. Proc. Natl. Acad. Sci. USA 94, 4318–4323 (1997).
Altiok, S., Xu, M. & Spiegelman, B.M. PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA binding activity via downregulation of PP2A. Genes Dev. 11, 1987–1998 ( 1997).
Tontonoz, P. et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor- gamma and the retinoid X receptor. Proc. Natl. Acad. Sci. USA 94, 237–241 (1997).
Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J. & Glass, C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79–82 (1998).
Jiang, C., Ting, A.T. & Seed, B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82– 86 (1998).
Mansen, A., Guardiola-Diaz, H., Rafter, J., Branting, C. & Gustafsson, J.A. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem. Biophys. Res. Commun. 222, 844– 851 (1996).
Auboeuf, D. et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients. Diabetes 46, 1319–1327 ( 1997).
DuBois, R.N. et al. The Nuclear Eicosanoid Receptor, PPARγ, is aberrantly expressed in Colonic Cancers. Carcinogenesis 19, 49–53 (1998).
Menck, H.R. et al. Clinical highlights from the National Cancer Data Base:1997. CA Cancer J. Clin. 47, 161– 170 (1997).
Chantret, I., Barbat, A., Dussaulx, E., Brattain, M.G. & Zweibaum, A. Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines. Cancer Res 48, 1936– 1942 (1988).
Kawai, K. et al. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimittelforschung 47, 356–368 (1997).
Thomas, P. in Metastatic Potential of Human Colorectal Cancer Cell Lines, 1– 94 (R. G. Landes, Austin, Texas, 1993).
Kondoh, N., Schweinfest, C.W., Henderson, K.W. & Papas, T.S. Differential expression of S19 ribosomal protein, laminin-binding protein, and human lymphocyte antigen class I messenger RNAs associated with colon carcinoma progression and differentiation. Cancer Res. 52, 791–796 (1992).
Zhang, L. et al. Gene expression profiles in normal and cancer cells. Science 276, 1268–1272 ( 1997).
Mafune, K. et al. Expression of a Mr 32,000 laminin-binding protein messenger RNA in human colon carcinoma correlates with disease progression. Cancer Res. 50, 3888–3891 (1990).
Tomlinson, I.P. & Bodmer, W.F. Failure of programmed cell death and differentiation as causes of tumors: some simple mathematical models. Proc. Natl. Acad. Sci. USA 92, 11130 –11134 (1995).
Kinzler, K.W. & Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 87, 159–170 (1996).
Kohl, N.E. et al. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA 91, 9141–9145 (1994).
Dudley, D.T., Pang, L., Decker, S.J., Bridges, A.J. & Saltiel, A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92, 7686–7689 (1995).
Selivanova, G. et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nature Med. 3, 632–638 ( 1997).
Gordon, J.I., Schmidt, G.H. & Roth, K.A. Studies of intestinal stem cells using normal, chimeric, and transgenic mice. FASEB J 6, 3039– 3050 (1992).
Hu, E., Kim, J.B., Sarraf, P. & Spiegelman, B.M. Inhibition of adipogenesis through MAP Kinase-mediated phosphorylation of PPARgamma. Science 274, 2100–2103 (1996).
Mueller, E. et al. Terminal Differentiation of Human Breast Cancer through PPARγ. Molecular Cell 1, 465– 470 (1998).
Nolan, J.J., Ludvik, B., Beerdsen, P., Joyce, M. & Olefsky, J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 331, 1188–1193 (1994).
Levy, G.N. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J 11, 234– 247 (1997).
Acknowledgements
We thank I. Summerhayes and P. Thomas for materials and discussion, and P. Lepage and E. Rosen for critically reviewing the manuscript. We also thank A. Levens for assistance in the preparation of this manuscript. This work was supported by grants from the NIH (R37 DK-31405), Novartis, Inc., and a Johnson & Johnson Research Award.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sarraf, P., Mueller, E., Jones, D. et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 4, 1046–1052 (1998). https://doi.org/10.1038/2030
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/2030
This article is cited by
-
Rosuvastatin alleviated the liver ischemia reperfusion injury by activating the expression of peroxisome proliferator-activated receptor gamma (PPARγ)
Journal of Bioenergetics and Biomembranes (2021)
-
Epigenetic derepression converts PPARγ into a druggable target in triple-negative and endocrine-resistant breast cancers
Cell Death Discovery (2021)
-
Triglyceride–glucose index (TyG index) is a predictor of incident colorectal cancer: a population-based longitudinal study
BMC Endocrine Disorders (2020)
-
PRMT1 inhibition induces differentiation of colon cancer cells
Scientific Reports (2020)
-
Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer
Scientific Reports (2020)